Current Treatment of Malignant Mesothelioma
Article Sidebar
Published:
Feb 20, 2017
Keywords:
malignant mesothelioma, chemotherapy for mesothelioma, asbestos, monoclonal antibody therapy
Main Article Content
Abstract
Malignant mesothelioma is a cancer of the mesothelium. Although mesothelioma is a rare malignancy, it has a poor prognosis. The incidence rate of malignant mesothelioma has been rising since the mid twentieth century century. Asbestos is the most common cause of mesothelioma. Chemotherapy combined with radiation therapy is currently the best choice of treatment and monoclonal antibody therapy is a new treatment option for the future. In the present study, we thoroughly reviewed the pathogenesis, clinical features, laboratory diagnosis, modalities of treatment, and clinical outcomes of this condition.
Article Details
How to Cite
1.
Bunman S. Current Treatment of Malignant Mesothelioma. BKK Med J [Internet]. 2017 Feb. 20 [cited 2024 Apr. 24];13(1):95. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/221811
Section
Reviews Article
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
1. Albin M, Magnani C, Krstev S, et al. Asbestos and cancer:An overview of current trends in Europe. Environ Health Perspect 1999;107 (Suppl 2):289-98.
2. Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89(10):716-24.
3. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
4. Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002;41:188-201.
5. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007;45:379-87.
6. Bovornkitti S. Asbestos and mesothelioma in Thailand.Thammasat Med J 2012;11:642-50.
7. Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in Norway: a populationbased study of 1,686 cases. J Thorac Oncol 2012;7:1858-61.
8. Offermans NS, Vermeulen R, Burdorf A, et al. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in a prospective Netherlands cohort study. J Occup Environ Med 2014;56:6-19.
9. Markowitz S. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. Semin Respir Crit Care Med 2015;36:334-46.
10. Farioli A, Ottone M, Morganti AG, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med 2016;5:950-9.
11. Farioli A, Violante FS, Mattioli S, et al. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database. Cancer Causes Control 2013;24(8):1535-45.
12. Qi F, Carbone M, Yang H, et al. Simian virus 40 transformation,malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011;5:683-97.
13. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993;142:1524-33.
14. Carbone M, Rizzo P, Grimley PM, et al. Simian virus 40 large T antigen binds in human mesotheliomas. Nat Med 1997;3:908-12.
15. Sardar MR, Kuntz C, Patel T, et al. Primary pericardial mesothelioma unique case and literature review. Tex Heart Inst J 2012;39:261-4.
16. Nielsen LS, Baelum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer-a systematic review of the literature. Arch Environ Occup Health 2014;69:191-206.
17. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
18. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17
19. Godar M, Liu J, Zhang P, et al. Primary pericardial mesothelioma:a rare entity. Case Rep Oncol Med 2013;2013:283601.
20. Suman S, Schofield P, Large S. Primary pericardial mesothelioma presenting as pericardial constriction: a case report. Heart 2004;90:e4.
21. Eryilmaz S, Sirlak M, Inan MB, et al. Primary pericardial mesothelioma. Cardiovasc Pathol 2001;10:147-9.
22. Montón CS, Esparza JFO, Ventura AB, et al. Mesothelioma of the tunica vaginalis in a patient with giant hydrocele. Radiol Bras 2016;49:63-4.
23. Parcesepe P, Sina S, Zanella C, et al. Case Report of a WellDifferentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature. Int JSurg Pathol 2016;24:443-7.
24. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-8.
25. Righi L, Duregon E, Vatrano S, et al. Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study. J Thorac Oncol 2016;11(11):2006-17.
26. Matsuzaki H, Lee S, Kumakai-Takein N, et al. Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma. Kawasaki Med J 2015;4:13-22.
27. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma:clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307-13.
28. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma ofthe pleura. A phase II study. Br J Cancer 1992;65:956-60.
29. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17 (Suppl 5):v7-12.
30. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
31. Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427-36.
32. Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev 2011;7:214-20.
33. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition: a critical review. Anticancer Agents Med Chem 2007;7:223-45.
34. Hellstrom I, Friedman E, Verch T, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:1520-6.
35. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics 2008;2:601-9.
2. Delgermaa V, Takahashi K, Park EK, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89(10):716-24.
3. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
4. Leigh J, Davidson P, Hendrie L, et al. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 2002;41:188-201.
5. Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 2007;45:379-87.
6. Bovornkitti S. Asbestos and mesothelioma in Thailand.Thammasat Med J 2012;11:642-50.
7. Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in Norway: a populationbased study of 1,686 cases. J Thorac Oncol 2012;7:1858-61.
8. Offermans NS, Vermeulen R, Burdorf A, et al. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in a prospective Netherlands cohort study. J Occup Environ Med 2014;56:6-19.
9. Markowitz S. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. Semin Respir Crit Care Med 2015;36:334-46.
10. Farioli A, Ottone M, Morganti AG, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med 2016;5:950-9.
11. Farioli A, Violante FS, Mattioli S, et al. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database. Cancer Causes Control 2013;24(8):1535-45.
12. Qi F, Carbone M, Yang H, et al. Simian virus 40 transformation,malignant mesothelioma and brain tumors. Expert Rev Respir Med 2011;5:683-97.
13. Cicala C, Pompetti F, Carbone M. SV40 induces mesotheliomas in hamsters. Am J Pathol 1993;142:1524-33.
14. Carbone M, Rizzo P, Grimley PM, et al. Simian virus 40 large T antigen binds in human mesotheliomas. Nat Med 1997;3:908-12.
15. Sardar MR, Kuntz C, Patel T, et al. Primary pericardial mesothelioma unique case and literature review. Tex Heart Inst J 2012;39:261-4.
16. Nielsen LS, Baelum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer-a systematic review of the literature. Arch Environ Occup Health 2014;69:191-206.
17. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg 2012;1:491-6.
18. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17
19. Godar M, Liu J, Zhang P, et al. Primary pericardial mesothelioma:a rare entity. Case Rep Oncol Med 2013;2013:283601.
20. Suman S, Schofield P, Large S. Primary pericardial mesothelioma presenting as pericardial constriction: a case report. Heart 2004;90:e4.
21. Eryilmaz S, Sirlak M, Inan MB, et al. Primary pericardial mesothelioma. Cardiovasc Pathol 2001;10:147-9.
22. Montón CS, Esparza JFO, Ventura AB, et al. Mesothelioma of the tunica vaginalis in a patient with giant hydrocele. Radiol Bras 2016;49:63-4.
23. Parcesepe P, Sina S, Zanella C, et al. Case Report of a WellDifferentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature. Int JSurg Pathol 2016;24:443-7.
24. Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-8.
25. Righi L, Duregon E, Vatrano S, et al. Brca1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: a Large Retrospective Study. J Thorac Oncol 2016;11(11):2006-17.
26. Matsuzaki H, Lee S, Kumakai-Takein N, et al. Investigating methods regarding diagnostic and prognostic biomarkers for malignant mesothelioma. Kawasaki Med J 2015;4:13-22.
27. Borasio P, Berruti A, Bille A, et al. Malignant pleural mesothelioma:clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg 2008;33:307-13.
28. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma ofthe pleura. A phase II study. Br J Cancer 1992;65:956-60.
29. Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17 (Suppl 5):v7-12.
30. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22:3-10.
31. Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003;2:427-36.
32. Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev 2011;7:214-20.
33. Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition: a critical review. Anticancer Agents Med Chem 2007;7:223-45.
34. Hellstrom I, Friedman E, Verch T, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008;17:1520-6.
35. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics 2008;2:601-9.